Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 25, 2026, 4:05 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 97–120 of 2,220 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: ADD Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Trial to Characterize Differences in Blood Levels of Different Lots of Centanafadine QD XR and to Understand the Effect of Food on Blood Levels

NCT07253441
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
CTN XR (TBM), CTN SR, CTN XR (Clin)
Drug
Lead sponsor
Otsuka Pharmaceutical Development & Commercialization, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
174 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
2
States / cities
Lenexa, Kansas • Millcreek, Utah
Source: ClinicalTrials.gov public record
Updated Dec 11, 2025 · Synced Oct 25, 2026, 4:05 AM EDT
Recruiting Not applicable Interventional

Enhancing Team Effectiveness for a Collaborative School-based Intervention for ADHD

NCT06180681
View directory record Official record
Conditions
Team-effectiveness Research, School-based Interventions, Attention Deficit/ Hyperactivity Disorder, Implementation Science
Interventions
Team-Enhanced Collaborative Life Skills Program, Standard Collaborative Life Skills Program
Behavioral
Lead sponsor
University of California, San Diego
Other
Eligibility
7 Years to 11 Years
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2028
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Jun 30, 2026 · Synced Oct 25, 2026, 4:05 AM EDT
Completed Phase 1 Interventional

Effects of Using Betahistine to Treat Adults With Attention Deficit Hyperactivity Disorder

NCT00829881
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Betahistine Hydrochloride, Placebo Capsule
Drug
Lead sponsor
P2D, Inc.
Industry
Eligibility
22 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 26, 2013 · Synced Oct 25, 2026, 4:05 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Evaluation of a Beverage Media Campaign and Added-sugar Warning Labels

NCT05563181
View directory record Official record
Conditions
Attitude, Intention
Interventions
Control bar code label, Warning label, Informational campaign poster about added-sugar warning labels
Behavioral
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 99 Years
Enrollment
2,275 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated Aug 1, 2025 · Synced Oct 25, 2026, 4:05 AM EDT
Completed Phase 3 Interventional

Safety & Tolerability of MTS in Children Aged 6-12 Diagnosed With ADHD & Previously Treated With Extended-Release Methylphenidate Therapy

NCT00151983
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
Methylphenidate Transdermal System
Drug
Lead sponsor
Noven Therapeutics
Industry
Eligibility
6 Years to 12 Years
Enrollment
175 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
18
States / cities
Scottsdale, Arizona • San Marcos, California • Boulder, Colorado + 15 more
Source: ClinicalTrials.gov public record
Updated Jul 9, 2015 · Synced Oct 25, 2026, 4:05 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Nicotine, Non-Smokers With and Without ADHD, and Genetics Study

NCT01819259
View directory record Official record
Conditions
Non-smoker, ADHD
Interventions
Nicotine nasal spray, Placebo
Drug
Lead sponsor
Scott Kollins, PhD
Other
Eligibility
18 Years to 25 Years
Enrollment
136 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 30, 2018 · Synced Oct 25, 2026, 4:05 AM EDT
Completed Phase 3 Interventional

Study to Assess the Safety and Efficacy of NRP104 in Adults With Attention-Deficit Hyperactivity Disorder (ADHD)

NCT00334880
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder, Attention Deficit Disorders With Hyperactivity, Attention Deficit Hyperactivity Disorders
Interventions
NRP104
Drug
Lead sponsor
New River Pharmaceuticals
Industry
Eligibility
18 Years to 55 Years
Enrollment
420 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006
U.S. locations
48
States / cities
Little Rock, Arkansas • El Centro, California • Irvine, California + 43 more
Source: ClinicalTrials.gov public record
Updated Jul 2, 2009 · Synced Oct 25, 2026, 4:05 AM EDT
Completed No phase listed Observational

Attention Deficit/Hyperactivity Disorder Internet Survey Study in a College Student Population

NCT02251080
View directory record Official record
Conditions
Attention Deficit Hyperactivity Disorder
Interventions
Not listed
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 20, 2017 · Synced Oct 25, 2026, 4:05 AM EDT
Completed Phase 3 Interventional Results available

A Study of the Efficacy and Safety of Pregabalin as Add-On Therapy for Partial Onset Seizures in Children Ages 4-16 Years

NCT01389596
View directory record Official record
Conditions
Epilepsy, Partial Seizures
Interventions
Pregabalin add-on therapy
Drug
Lead sponsor
Pfizer's Upjohn has merged with Mylan to form Viatris Inc.
Industry
Eligibility
4 Years to 16 Years
Enrollment
295 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2016
U.S. locations
20
States / cities
Tucson, Arizona • Little Rock, Arkansas • Los Angeles, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jan 20, 2021 · Synced Oct 25, 2026, 4:05 AM EDT
Completed Phase 4 Interventional Results available

Allopurinol Add-on Treatment for Refractory Mania

NCT00643123
View directory record Official record
Conditions
Bipolar Disorder, Mixed Mania, Treatment-Resistant Mania
Interventions
Allopurinol, Placebo
Drug · Other
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated May 8, 2019 · Synced Oct 25, 2026, 4:05 AM EDT
Not yet recruiting Phase 4 Interventional

Methylprednisolone Addition to Multimodal Pain Regimens After Anterior Cruciate Ligament Reconstruction

NCT07605923
View directory record Official record
Conditions
ACL Reconstruction
Interventions
Methyl Prednisolone (MP), Standard Post-Operative Pain Control, Surgeon's Standard ACL Postoperative Regimen
Drug · Combination Product
Lead sponsor
University of Alabama at Birmingham
Other
Eligibility
14 Years to 65 Years
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
1
States / cities
Birmingham, Alabama
Source: ClinicalTrials.gov public record
Updated May 26, 2026 · Synced Oct 25, 2026, 4:05 AM EDT
Withdrawn Phase 3 Interventional

Safety Study of Rufinamide Given as an add-on Therapy to Treat Patients With Seizures

NCT04558580
View directory record Official record
Conditions
Refractory Partial Seizures
Interventions
Rufinamide
Drug
Lead sponsor
University of South Alabama
Other
Eligibility
12 Years to 80 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
Mobile, Alabama
Source: ClinicalTrials.gov public record
Updated Sep 22, 2020 · Synced Oct 25, 2026, 4:05 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Brain Plasticity Underlying Acquisition of New Organizational Skills in Children-R61 Phase

NCT03148782
View directory record Official record
Conditions
ADHD, Attention Deficit Hyperactivity Disorder, Neurodevelopmental Disorders
Interventions
OST Intervention for participants with Organizational skill difficulties
Behavioral
Lead sponsor
NYU Langone Health
Other
Eligibility
8 Years to 11 Years
Enrollment
42 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 1, 2019 · Synced Oct 25, 2026, 4:05 AM EDT
Completed Phase 2 Interventional

A Phase II Study to Evaluate the Additivity of Trabodenoson to Latanoprost in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma

NCT01917383
View directory record Official record
Conditions
Primary Open-Angle Glaucoma (POAG), Ocular Hypertension (OHT)
Interventions
Trabodenoson, Latanoprost, Timolol
Drug
Lead sponsor
Inotek Pharmaceuticals Corporation
Industry
Eligibility
18 Years and older
Enrollment
101 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
1
States / cities
Bristol, Tennessee
Source: ClinicalTrials.gov public record
Updated Dec 2, 2017 · Synced Oct 25, 2026, 4:05 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

The Effects of Cannabigerol on Attention-Deficit/Hyperactivity Disorder

NCT06115603
View directory record Official record
Conditions
Attention-Deficit/Hyperactivity Disorder
Interventions
Cannabigerol, Placebo
Drug · Other
Lead sponsor
University of Arkansas, Fayetteville
Other
Eligibility
18 Years to 55 Years
Enrollment
76 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2026
U.S. locations
1
States / cities
Fayetteville, Arkansas
Source: ClinicalTrials.gov public record
Updated May 27, 2026 · Synced Oct 25, 2026, 4:05 AM EDT
Terminated Phase 2 Interventional Results available

Efficacy and Safety of OncoGel™ Added to Chemotherapy and Radiation Before Surgery in Subjects With Esophageal Cancer

NCT00573131
View directory record Official record
Conditions
Esophageal Cancer, Adenocarcinoma of the Esophagus, Squamous Cell Carcinoma
Interventions
OncoGel (Paclitaxel gel), cisplatin, 5-FU, radiation therapy, esophageal resection
Drug · Radiation · Procedure
Lead sponsor
Boston Scientific Corporation
Industry
Eligibility
18 Years and older
Enrollment
137 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
8
States / cities
San Diego, California • Chicago, Illinois • Indianapolis, Indiana + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2022 · Synced Oct 25, 2026, 4:05 AM EDT
Recruiting Phase 2 Interventional

Amping up With PemJAK

NCT07283822
View directory record Official record
Conditions
Non-Hodgkin Lymphoma, Hodgkin Disease Lymphoma, Non-Hodgkin Lymphoma Refractory/ Relapsed, Hodgkin Disease Recurrent, Gray Zone Lymphoma, Peripheral T-cell Lymphoma, Cutaneous T-Cell Lymphomas, Primary Mediastinal B Cell Lymphoma
Interventions
Ruxolitinib, Pembrolizumab
Drug
Lead sponsor
Seda S. Tolu
Other
Eligibility
18 Years to 95 Years
Enrollment
53 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2029
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Dec 16, 2025 · Synced Oct 25, 2026, 4:05 AM EDT
Recruiting Not applicable Interventional

Pediatric Epilepsy

NCT07350551
View directory record Official record
Conditions
Epilepsy Intractable
Interventions
Cedrus RB series response pad; Adtech Behnke-Fried micro-electrodes; Neuralynx or Blackrock electrophysiology system; Blackrock Cerestim or Natus Nicolet stimulator
Behavioral
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
3 Years to 25 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2032
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Oct 6, 2026 · Synced Oct 25, 2026, 4:05 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Vascular Effects of Attention Deficit Hyperactivity Disorder (ADHD) Medications in Youth

NCT01107301
View directory record Official record
Conditions
ADHD
Interventions
Not listed
Lead sponsor
University of Minnesota
Other
Eligibility
6 Years to 18 Years
Enrollment
138 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2013
U.S. locations
1
States / cities
Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Sep 5, 2014 · Synced Oct 25, 2026, 4:05 AM EDT
Completed Phase 2 Interventional Results available

Double Blinded, Placebo-Controlled Trial of Paliperidone Addition in SRI-Resistant Obsessive-Compulsive Disorder

NCT00632229
View directory record Official record
Conditions
Obsessive-Compulsive Disorder
Interventions
Paliperidone, Placebo
Drug
Lead sponsor
University of South Florida
Other
Eligibility
18 Years to 70 Years
Enrollment
34 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2013
U.S. locations
2
States / cities
St. Petersburg, Florida • Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Feb 6, 2014 · Synced Oct 25, 2026, 4:05 AM EDT
Completed Phase 2 Interventional

A Dose-Ranging, Cross-over Study of the Safety and Efficacy of ABT-089 in Adults With Attention-Deficit/Hyperactivity Disorder (ADHD)

NCT00391729
View directory record Official record
Conditions
Attention-Deficit/Hyperactivity Disorder
Interventions
ABT-089, Placebo
Drug
Lead sponsor
Abbott
Industry
Eligibility
18 Years to 60 Years
Enrollment
221 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
23
States / cities
Mesa, Arizona • Lafayette, California • Oceanside, California + 20 more
Source: ClinicalTrials.gov public record
Updated Oct 18, 2011 · Synced Oct 25, 2026, 4:05 AM EDT
Completed No phase listed Observational

A Study of Label Compliance for Attention Deficit/Hyperactivity Disorder (ADHD) Medications in Japan

NCT04113551
View directory record Official record
Conditions
Attention Deficit Disorder With Hyperactivity
Interventions
MPH (Concerta), MPH (Ritalin), Atomoxetine (ATO), Guanfacine (GFC)
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
Not listed
Enrollment
17,418 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Titusville, New Jersey
Source: ClinicalTrials.gov public record
Updated Apr 27, 2025 · Synced Oct 25, 2026, 4:05 AM EDT
Recruiting Not applicable Interventional Accepts healthy volunteers

A Sensory Strategy to Cut Sugary Beverages in African/American and Latine Adolescents

NCT07223151
View directory record Official record
Conditions
Obesity, Adolescent, Dietary Sugars, Taste Perception, Insulin Resistance, Feeding Behavior
Interventions
Unsweetened Sparkling Water Replacement, Progressively Reduced Sugar Beverage Replacement, Plain Water Replacement
Behavioral
Lead sponsor
Nana Gletsu Miller
Other
Eligibility
12 Years to 18 Years
Enrollment
63 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
3
States / cities
Bloomington, Indiana • Indianapolis, Indiana • West Lafayette, Indiana
Source: ClinicalTrials.gov public record
Updated Aug 6, 2026 · Synced Oct 25, 2026, 4:05 AM EDT